High Doses of Ambisome in the Treatment of Invasive aspergillosis (IA).

I. RUIZ, T. OLIVE, J. GAVALDA, A. JULIA, A. MORENO, C. LUMBRERAS, J.M. CISNEROS, J.R. AZANZA, A. PAHISSA

Author address: 

I. RUIZ, T. OLIVE1, J. GAVALDA, A. JULIA, A. MORENO, C. LUMBRERAS, J.M. CISNEROS, J.R. AZANZA5, A. PAHISSA

Abstract: 

Background: New strategies are necessary to reduce the high mortality rate of IA in immunocompromissed patients. Previous studies have suggested the safety and tolerability of high doses of Ambisome. We present our experience using them. Methods: A retrospective evaluation of 13 patients with IA who received 10 mg/Kg/day of Ambisome was conducted. Diagnosis was based on clinical, radiographic (CT), and microbiologic data. Response to Ambisome was graded as either successful (partial or complete response) or failure. Results: 13 patients(10 hematological patients, 2 solid organ transplant recipients and one AIDS patient) received Ambisome. The IA was proven: 2, probable: 8, and possible: 3. Pulmonary IA was present in 8 cases, disseminated disease affecting the CNS occurred in 3 patients, and sinusal IA in 2 cases. All patients received steroids and 4 out of 13 patients received itraconazole as antifungal prophylaxis. 8 out of 13 patients had neutropenia (
2003

abstract No: 

M-966

Full conference title: 

43rd Interscience Conference on Antimicrobial Agents
    • ICAAC 43rd